Clean Science FY26: Margins held up, while HALS began to scale

Clean Science and Technology ended Q4 FY2026 with a clear message: demand and pricing were tough for much of the year, but execution held steady and the quarter showed sequential improvement. On a standalone basis, Q4 revenue was Rs. 197 crore (up 6% QoQ, down 20% YoY). EBITDA came in at Rs. 88 crore with a 45.6% margin, while PAT was Rs. 58 crore. The year, however, was weaker on revenue. Standalone FY2026 revenue fell to Rs. 815 crore from Rs. 922 crore in FY2025, with management attributing the decline to a loss of a key FMCG account in 4-MAP, muted offtake, and pricing pressure across select products and geographies.

What stood out was profitability resilience. FY2026 standalone EBITDA was Rs. 353 crore and the EBITDA margin stayed at 44.3%, broadly unchanged from FY2025. The company’s narrative is consistent with its positioning as a process-led specialty chemical player, where manufacturing efficiency and product mix can cushion earnings even when volumes soften.

Consolidated performance told a slightly different story, reflecting the growing role of the group’s HALS business housed in its wholly owned subsidiary Clean Fino Chem. Consolidated Q4 revenue rose 14% QoQ to Rs. 249 crore, and full-year consolidated revenue was broadly flat at Rs. 957 crore. Management emphasized that HALS delivered its highest ever quarterly revenue in Q4 and that the subsidiary reported its first quarter of positive EBITDA.

A year of two stories: standalone softness, consolidated stability

Standalone FY2026 revenue decline of 12% contrasted with consolidated revenue that stayed almost unchanged year-on-year. The main swing factor was the subsidiary’s scale-up. On the call, management described FY2026 as a year where challenging global conditions persisted, including geopolitical uncertainty, tariff-related uncertainty, muted customer offtake, and pricing pressure. Despite that, Q4 saw sequential improvement driven largely by higher customer offtake volumes.

The company also shared the segment mix for FY2026 standalone revenues: Performance Chemicals accounted for 72%, Pharma-Agro intermediates 19%, and FMCG chemicals 9%. While this does not provide product-level granularity, it confirms that the performance chemicals portfolio remains the primary earnings engine.

HALS begins to show the operating leverage

The clearest operational momentum discussed on the call was HALS. Management described the Q4 uptick as a delayed conversion of customer trials and validations into scale orders. Earlier, the HALS business was focused on India import substitution, with management indicating it had been roughly 80% domestic and 20% exports at one stage. Over time, exports have picked up materially, with management indicating that in select products they are now at about 50% exports.

Some verifiable operating data points were shared. Management stated that HALS volumes were over 1,000 tonnes for the quarter. It also shared that March exit utilization was around 40% and that blended realization was around Rs. 460 per kg, up from roughly Rs. 420 to Rs. 430 per kg in the prior quarter. The company also linked improving subsidiary profitability to a more favorable mix, as higher grade HALS products started selling on a larger scale. This mix shift, combined with spreading fixed costs over a larger base, was cited as the driver for margin expansion.

Management also acknowledged cost headwinds. Acetone and ammonia prices were cited as having risen sharply, which matters for amine-based HALS chemistries. Even so, the company noted that the subsidiary moved from EBITDA neutral in Q3 to a positive EBITDA in Q4.

Capex, integration, and stabilization: HQ/Catechol and PC2

The company incurred total capex of about Rs. 220 crore during FY2026, primarily toward Clean Fino Chem. Management added that capital infusion into the subsidiary was about Rs. 200 crore in FY26, taking total investments in the subsidiary to about Rs. 750 crore.

Beyond HALS, the other major project discussed was Hydroquinone and Catechol. Management said the plant was established in December 2025 and is under an initial stabilization phase. It expects the plant to achieve optimal operations with improved productivity and efficiency in the following 1 to 2 quarters. Customer quality approvals have been secured. A key near-term benefit described was captive substitution: during the quarter, HQ and Catechol imports were fully replaced by captive production for TBHQ and Veratrole, leading to moderation in raw material costs. However, management also stated that utilization was still low, around 10% to 15% at present.

On Performance Chemical 2, management stated that the capex timeline is on track and expects commercialization by September 2026. It also acknowledged that changes in commissioning timeline were attributable to scarce manpower resources, with labor movement observed due to higher gas prices.

In HALS, management highlighted further backward integration into key starting materials and raw materials to strengthen supply reliability and improve margins, stating it would be implemented with minimal capital expenditure using in-house developed processes. It also mentioned debottlenecking some HALS lines and setting up a dedicated line for HALS 2020, described as a key intermediate for higher grade NOR-HALS products.

Governance and capital allocation signals

Two decisions stood out as explicit capital allocation signals. First, promoter directors voluntarily elected to forgo a substantial portion of their performance bonus for FY2026. Management stated performance bonus for FY26 was reduced to less than 1% of PBT versus an entitlement of 4% of PBT, and quantified a reversal of about Rs. 11 crore.

Second, the board approved a final dividend of Rs. 4 per share, and the investor presentation stated the total payout ratio for the year was 25%. The company also reiterated its zero debt position.

Takeaways

Clean Science finished FY2026 with stable standalone margins despite a meaningful revenue decline, and with consolidated revenue held steady through subsidiary scale-up. The headline near-term watch items are execution-led: whether HALS continues to improve its mix and utilization, whether Hydroquinone and Catechol stabilizes over the next 1 to 2 quarters, and whether Performance Chemical 2 meets the stated September 2026 commercialization timeline.

Management did not provide numerical guidance for FY27 operating performance, citing macro and crude-linked uncertainty and China-related pricing arbitrage. In that context, the company’s next phase appears to hinge less on incremental efficiency and more on how quickly new assets and product lines convert into sustained volumes at acceptable pricing.